VOR · Insider Trading
Vor Biopharma Inc. Common Stock
Every open-market purchase and sale reported by VOR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | RA Capital Healthcare Fund LP | 10%+ Owner | M | +2,000 | +$25.60K |
| 2026-08-26 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | M | +6,000 | +$22.42K |
| 2026-07-21 | Peter Kolchinsky | 10%+ Owner | MIXED | +8,399,148 | −$27 |
| 2026-07-09 | David Zaccardelli | Director | A | +42,658 deriv. | — |
| 2026-06-12 | Daniella Beckman | Director | A | +53,283 deriv. | — |
| 2026-06-12 | Alexander Cumbo | Director | A | +56,345 deriv. | — |
| 2026-06-12 | Erez Kalir | Director | A | +57,162 deriv. | — |
| 2026-06-12 | Andrew David Levin | Director | A | +57,162 deriv. | — |
| 2026-06-12 | Michel Detheux | Director | A | +57,162 deriv. | — |
| 2026-06-12 | Fouad Namouni | Director | A | +56,549 deriv. | — |
| 2026-06-12 | Wouter Joustra | Director | A | +57,162 deriv. | — |
| 2026-06-12 | RA Capital Healthcare Fund LP | Director | A | +228,648 deriv. | — |
| 2026-04-24 | RA Capital Healthcare Fund LP | Director | Sell | −660,600 | −$10.42M |
| 2026-04-21 | Peter Kolchinsky | Director | Sell | −2,521,496 | −$40.70M |
| 2026-04-15 | RA Capital Healthcare Fund LP | Director | Sell | −2,951,956 | −$47.53M |
| 2026-04-10 | Rajeev M. Shah | Director | Sell | −2,480,532 | −$40.94M |
| 2026-04-06 | Peter Kolchinsky | Director | Sell | −3,397,028 | −$58.08M |
| 2025-12-19 | Wouter Joustra | Director | A | +3,000 deriv. | — |
| 2025-12-19 | Andrew David Levin | Director | A | +3,000 deriv. | — |
| 2025-12-19 | RA Capital Healthcare Fund LP | Director | A | −18,501,384 | −$200.00M |
| 2025-12-09 | Jean-Paul Kress | CEO and Chairman | MIXED | — | — |
| 2025-12-09 | Qing Che Zuraw | Chief Development Officer | MIXED | — | — |
| 2025-12-09 | Sandesh Mahatme | CFO | D | −694,137 | — |
| 2025-10-30 | Peter Kolchinsky | Director | Sell | −1,601,632 | −$41.48M |
| 2025-10-27 | Rajeev M. Shah | Director | Sell | −884,664 | −$24.82M |
| 2025-10-22 | Rajeev M. Shah | Director | Sell | −585,250 | −$17.17M |
| 2025-10-21 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | −75,066 | −$2.27M |
| 2025-10-17 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | −147,352 | −$4.70M |
| 2025-10-17 | RA Capital Healthcare Fund LP | Director | Sell | −2,320,125 | −$68.54M |
| 2025-10-15 | Reid Hoffman | 10%+ Owner | Sell | −193,314 | −$6.01M |
| 2025-10-10 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | −248,292 | −$8.23M |
| 2025-10-08 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | −196,774 | −$7.11M |
| 2025-10-03 | Reid Hoffman | 10%+ Owner | Sell | −83,504 | −$3.29M |
| 2025-09-22 | Peter Kolchinsky | Director | A | +50,000,000 deriv. | — |
| 2025-09-18 | Reid Hoffman | 10%+ Owner | Sell | −894,556 | −$1.38M |
| 2025-09-15 | Reid Hoffman | 10%+ Owner | Sell | −1,969,610 | −$3.41M |
| 2025-09-10 | Sarah Burgess Reed | Director | A | +60,000 deriv. | — |
| 2025-09-10 | Peter Kolchinsky | Director | A | +300,000 deriv. | — |
| 2025-09-10 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | −2,527,294 | −$4.92M |
| 2025-09-05 | Reid Hoffman | 10%+ Owner | Sell | −2,815,256 | −$5.54M |
| 2025-08-29 | Reid Hoffman | 10%+ Owner | Sell | −2,835,996 | −$5.70M |
| 2025-08-27 | Reid Hoffman | 10%+ Owner | Sell | −1,343,072 | −$2.82M |
| 2025-07-30 | Qing Che Zuraw | Chief Development Officer | A | +937,080 | — |
| 2025-07-18 | Michel Detheux | Director | A | +60,000 deriv. | — |
| 2025-07-18 | Alexander Cumbo | Director | A | +60,000 deriv. | — |
| 2025-07-10 | Sandesh Mahatme | CFO | A | +13,882,750 | — |
| 2025-06-27 | Jean-Paul Kress | CEO and Chairman | A | +83,296,638 deriv. | — |
| 2025-05-23 | Joshua Resnick | Director | A | +30,000 deriv. | — |
| 2025-05-23 | Fouad Namouni | Director | A | +30,000 deriv. | — |
| 2025-05-23 | Matthew R Patterson | Director | A | +30,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Peter Kolchinsky | Director | 4,501,882 | $87.02M |
| Rajeev M. Shah | Director | 3,936,436 | $76.09M |
| RA Capital Nexus Fund, L.P. | Director | 1,891,036 | $36.55M |
| Reid Hoffman | 10%+ Owner | 1,333,792 | $25.78M |
| Reprogrammed Interchange LLC | 10%+ Owner | 1,178,725 | $22.78M |
| Qing Che Zuraw | Chief Development Officer | 46,854 | $905.69K |
| Robert Ang | PRESIDENT AND CEO | 45,566 | $880.80K |
| Tirtha Chakraborty | Chief Sci Off & Head Tech Ops | 10,871 | $210.14K |
| Eyal C. Attar | CHIEF MEDICAL OFFICER | 6,331 | $122.38K |
| Han Wook Choi | Chief Financial Officer | 2,564 | $49.56K |
| Amy Quinlan | Vice President of Finance | 2,516 | $48.63K |
| RA CAPITAL MANAGEMENT, L.P. | Director | 1,500 | $29.00K |
| RA Capital Healthcare Fund LP | Director | 500 | $9.67K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VOR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.